Approval of BI's Spiriva
Spiriva (tiotropium), from Boehringer Ingelheim, has completed the European Mutual Recognition Procedure (MRP). It is a novel compound designed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The MRP is based on the registration in the Netherlands, and means that national approvals in participating countries will be issued in the forthcoming months.